23 Oct 2026, 09:04 IST
Divi's Laboratories Limited
HDFC Securities · ADD · target INR 9,780
The report downgrades Divi's Laboratories to ADD from Buy with a revised target price of INR 9,780 based on 40x Q2FY29E EV/EBITDA, citing that near-term CDMO triggers including GLP-1 opportunities are already priced in after the stock's 40%/44%/43% rise over the last year/six months/since initiation.
From Divis Laboratories Update Oct26 HSIE, written by HDFC Securities. Orivam summarised it; the view is HDFC Securities's, not Orivam's.
Open the original PDF →Research PDFs are often removed by the firms that publish them. The summary above is kept so this page still means something if that happens.